-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Perform on Acadia Pharmaceuticals, Lowers Price Target to $21

Benzinga·11/18/2026 14:06:50
Listen to the news
Oppenheimer analyst Matthew Hershenhorn maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Perform and lowers the price target from $23 to $21.